Emerging drugs for sickle cell anemia

Expert Opinion on Emerging Drugs

Volumn 20, Issue 1, 2015, Pages 47-61

  Singh, Priya C ^a   Ballas, Samir K ^b  

^a Hematology Oncology   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Clinical trials; Emerging drugs; Hydroxyurea; Preventative therapy; Sickle cell; Sickle cell anemia; Sickle cell disease; Sickle cell therapy; Sickle cell treatment

Indexed keywords

ADJUVANT; ANALGESIC AGENT; FOLIC ACID; HEMOGLOBIN F; HYDROXYUREA; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; ANTISICKLING AGENT;

ACUPUNCTURE; BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CELL ADHESION; CRYOTHERAPY; GENE THERAPY; GUIDED IMAGERY; HUMAN; HYPERTHERMIC THERAPY; IMMUNIZATION; INFLAMMATION; MASSAGE; MEDITATION; MUSIC THERAPY; OXIDATIVE STRESS; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PSYCHOSOCIAL CARE; REVIEW; SICKLE CELL ANEMIA; TRANSCUTANEOUS NERVE STIMULATION; ANEMIA, SICKLE CELL; ANIMAL; DRUG DESIGN; MOLECULARLY TARGETED THERAPY;

ANEMIA, SICKLE CELL; ANIMALS; ANTISICKLING AGENTS; BLOOD TRANSFUSION; DRUG DESIGN; HUMANS; HYDROXYUREA; MOLECULAR TARGETED THERAPY;

EID: 84923295321     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2015.985587     Document Type: Review

References (85)

1. Odame I. Developing a global agenda for sickle cell disease: report of an international symposium and workshop in Cotonou, Republic of Benin. Am J Prev Med 2010; 38 (4 Suppl): S571-5
2. McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol 2011; 18 (3): 158-65
3. Castro O, Rana SR, Bang KM, Scott RB. Age and prevalence of sicklecell trait in a large ambulatory population. Genet Epidemiol 1987; 4 (4): 307-11
4. Steinberg MH, Forget BG, Higgs D R, Weatherall DJ. Disorders of hemoglobin. 2nd edition. Cambridge University; Cambridge: 2009
5. Goldsmith JC, Bonham VL, Joiner CH, et al. Framing the research agenda for sickle cell trait: building on the current understanding of clinical events and their potential implications. Am J Hematol 2012; 87 (3): 340-6
6. Serjeant GR, Serjeant BE. Sickle cell disease. 3d edition. Oxford University Press; Oxford: 2001
7. Bunn HF, Forget BG. Hemoglobin: molecular, genetic and clinical aspects. WB Saunders; Philadelphia: 1986
8. Ballas SK, Park D, Wapner RJ. Neonatal screening for sickle cell disease in a metropolitan university hospital: efficacy and problems. J Med Screen 1994; 1 (4): 229-32
9. Shafer FE, Lorey F, Cunningham GC, et al. Newborn screening for sickle cell disease: 4 years of experience from California's newborn screening program. J Pediatr Hematol Oncol 1996; 18 (1): 36-41
10. Diallo DA. Sickle cell disease in Africa: current situation and strategies for improving the quality and duration of survival. Bull Acad Natl Med 2008; 192 (7): 1361-72; discussion 72-3
11. Vichinsky E. Emerging 'A' therapies in hemoglobinopathies: agonists, antagonists, antioxidants, and arginine. Hematology Am Soc Hematol Educ Program 2012; 2012: 271-5
12. Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010; 115 (26): 5300-11
13. Ballas SK. Sickle cell pain. 2nd edition. International Association for the Study of Pain; Washington DC: 2014
14. Rees DC. The rationale for using hydroxycarbamide in the treatment of sickle cell disease. Haematologica 2011; 96 (4): 488-91
15. Kotiah SD, Ballas SK. Investigational drugs in sickle cell anemia. Expert Opin Investig Drugs 2009; 18 (12): 1817-28
16. Ballas SK. Sickle cell anaemia: progress in pathogenesis and treatment. Drugs 2002; 62 (8): 1143-72
17. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 2008; 358 (13): 1362-9
18. Platt OS, Orkin SH, Dover G, et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984; 74 (2): 652-6
19. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 2010; 85 (6): 403-8
20. Ballas SK, Bauserman RL, McCarthy WF, et al. Hydroxyurea and acute painful crises in sickle cell anemia: effects on hospital length of stay and opioid utilization during hospitalization, outpatient acute care contacts, and at home. J Pain Symptom Manage 2010; 40 (6): 870-82
21. Davies S, Olujohungbe A. Hydroxyurea for sickle cell disease. Cochrane Database Syst Rev 2001 (2): CD002202
22. Ballas SK, Marcolina MJ, Dover GJ, Barton FB. Erythropoietic activity in patients with sickle cell anaemia before and after treatment with hydroxyurea. Br J Haematol 1999; 105 (2): 491-6
23. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995; 332 (20): 1317-22
24. Charache S, Barton FB, Moore RD, et al. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Medicine 1996; 75 (6): 300-26
25. Alvarez O, Miller ST, Wang WC, et al. Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatr Blood Cancer 2012; 59 (4): 668-74
26. Armstrong FD, Elkin TD, Brown RC, et al. Developmental function in toddlers with sickle cell anemia. Pediatrics 2013; 131 (2): e406-14
27. Lebensburger JD, Miller ST, Howard TH, et al. Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatr Blood Cancer 2012; 59 (4): 675-8
28. McGann PT, Flanagan JM, Howard TA, et al. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG phase III clinical trial. Pediatr Blood Cancer 2012; 59 (2): 254-7
29. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011; 377 (9778): 1663-72
30. Ware RE, Rees RC, Sarnaik SA, et al. Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr 2010; 156 (1): 66-70
31. Kauf TL, Coates TD, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009; 84 (6): 323-7
32. Lanzkron S, Haywood C, Segal JB, Dover GJ. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea. Am J Hematol 2006; 81 (12): 927-32
33. Moore RD, Charache S, Terrin ML, et al. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. Am J Hematol 2000; 64 (1): 26-31
34. Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood 2000; 95 (4): 1130-6
35. Ballas SK. The cost of health care for patients with sickle cell disease. Am J Hematol 2009; 84 (6): 320-2
36. Manwani D, Frenette PS. Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies. Hematology Am Soc Hematol Educ Program 2013; 2013: 362-9
37. Kaul DK, Finnegan E, Barabino GA. Sickle red cell-endothelium interactions. Microcirculation 2009; 16 (1): 97-111
38. Madigan C, Malik P. Pathophysiology and therapy for haemoglobinopathies. Part I: sickle cell disease. Expert Rev Mol Med 2006; 8 (9): 1-23
39. Gutsaeva DR, Parkerson JB, Yerigenahally SD, et al. Inhibition of cell adhesion by anti-P-selectin aptamer: a new potential therapeutic agent for sickle cell disease. Blood 2011; 117 (2): 727-35
40. Turhan A, Weiss LA, Mohandas N, et al. Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci USA 2002; 99 (5): 3047-51
41. Zennadi R, Moeller BJ, Whalen EJ, et al. Epinephrine-induced activation of LW-mediated sickle cell adhesion and vaso-occlusion in vivo. Blood 2007; 110 (7): 2708-17
42. Hines PC, Zen Q, Burney SN, et al. Novel epinephrine and cyclic AMPmediated activation of BCAM/Ludependent sickle (SS) RBC adhesion. Blood 2003; 101 (8): 3281-7
43. Schaer DJ, Buehler PW, Alayash AI, et al. Hemolysis and free hemoglobin revisited: exploring hemoglobin and hemin scavengers as a novel class of therapeutic proteins. Blood 2013; 121 (8): 1276-84
44. Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005; 294 (1): 81-90
45. Kato GJ, Wang Z, Machado RF, et al. Endogenous nitric oxide synthase inhibitors in sickle cell disease: abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br J Haematol 2009; 145 (4): 506-13
46. Chantrathammachart P, Pawlinski R. Tissue factor and thrombin in sickle cell anemia. Thromb Res 2012; 129 (Suppl 2): S70-2
47. Chirico EN, Pialoux V. Role of oxidative stress in the pathogenesis of sickle cell disease. IUBMB Life 2012; 64 (1): 72-80
48. Gizi A, Papassotiriou I, Apostolakou F, et al. Assessment of oxidative stress in patients with sickle cell disease: the glutathione system and the oxidantantioxidant status. Blood Cells Mol Dis 2011; 46 (3): 220-5
49. Nur E, Biemond BJ, Otten HM, et al. Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management. Am J Hematol 2011; 86 (6): 484-9
50. Meiler SE, Wade M, Kutlar F, et al. Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice. Blood 2011; 118 (4): 1109-12
51. Kutlar A, Ataga K, Reid M, et al. A phase 1/2 trial of HQK-1001, an oral fetal globin inducer, in sickle cell disease. Am J Hematol 2012; 87 (11): 1017-21
52. Elias DB, Barbosa MC, Rocha LB, et al. L-arginine as an adjuvant drug in the treatment of sickle cell anaemia. Br J Haematol 2013; 160 (3): 410-12
53. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 2003; 102 (12): 3865-70
54. Lavelle D, Vaitkus K, Ling Y, et al. Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood 2012; 119 (5): 1240-7
55. Hebbel RP, Vercellotti GM, Pace BS, et al. The HDAC inhibitors trichostatin A and suberoylanilide hydroxamic acid exhibit multiple modalities of benefit for the vascular pathobiology of sickle transgenic mice. Blood 2010; 115 (12): 2483-90
56. GlycoMimetics Rivipansel in Pediatric Patients. GlycoMimetics Announces Presentation of Rivipansel Data in Pediatric Patients at American Society of Pediatric Hematology Oncology 27th Annual Meeting, Palmer House Hilton Hotel, Chicago, USA; 2014
57. Chang J, Patton JT, Sarkar A, et al. GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice. Blood 2010; 116 (10): 1779-86
58. Chang J, Shi PA, Chiang EY, Frenette PS. Intravenous immunoglobulins reverse acute vasoocclusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 2008; 111 (2): 915-23
59. Qari MH, Aljaouni SK, Alardawi MS, et al. Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial. Thromb Haemost 2007; 98 (2): 392-6
60. Kutlar A, Ataga KI, McMahon L, et al. A potent oral P-selectin blocking agent improves microcirculatory blood flow and a marker of endothelial cell injury in patients with sickle cell disease. Am J Hematol 2012; 87 (5): 536-9
61. De Castro LM, Zennadi R, Jonassaint JC, et al. Effect of propranolol as antiadhesive therapy in sickle cell disease. Clin Transl Sci 2012; 5 (6): 437-44
62. Lim MY, Ataga KI, Key NS. Hemostatic abnormalities in sickle cell disease. Curr Opin Hematol 2013; 20 (5): 472-7
63. Lee SP, Ataga KI, Zayed M, et al. Phase I study of eptifibatide in patients with sickle cell anaemia. Br J Haematol 2007; 139 (4): 612-20
64. Desai PC, Brittain JE, Jones SK, et al. A pilot study of eptifibatide for treatment of acute pain episodes in sickle cell disease. Thromb Res 2013; 132 (3): 341-5
65. Field JJ, Lin G, Okam MM, et al. Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood 2013; 121 (17): 3329-34
66. Scheuplein F, Thariath A, Macdonald S, et al. A humanized monoclonal antibody specific for invariant Natural Killer T (iNKT) cells for in vivo depletion. PLoS One 2013; 8 (9): e76692
67. Beckman JD, Belcher JD, Vineyard JV, et al. Inhaled carbon monoxide reduces leukocytosis in a murine model of sickle cell disease. Am J Physiol Heart Circ Physiol 2009; 297 (4): H1243-53
68. Belcher JD, Young M, Chen C, et al. MP4CO, a pegylated hemoglobin saturated with carbon monoxide, is a modulator of HO-1, inflammation, and vaso-occlusion in transgenic sickle mice. Blood 2013; 122 (15): 2757-64
69. Hoppe C, Kuypers F, Larkin S, et al. A pilot study of the short-term use of simvastatin in sickle cell disease: effects on markers of vascular dysfunction. Br J Haematol 2011; 153 (5): 655-63
70. Daak AA, Ghebremeskel K, Hassan Z, et al. Effect of omega-3 (n-3) fatty acid supplementation in patients with sickle cell anemia: randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 2013; 97 (1): 37-44
71. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of Nacetylcysteine actions. Cell Mol Life Sci 2003; 60 (1): 6-20
72. Pace BS, Shartava A, Pack-Mabien A, et al. Effects of N-acetylcysteine on dense cell formation in sickle cell disease. Am J Hematol 2003; 73 (1): 26-32
73. Jakubowski JA, Zhou C, Small DS, et al. A phase 1 study of prasugrel in subjects with sickle cell disease: effects on in vivo markers of platelet activation and of coagulation. Blood (ASH Annual Meeting Abstracts) 2011; 118: 1049
74. Jakubowski JA, Zhou C, Jurcevic S, et al. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res 2014; 133 (2): 190-5
75. Wun T, Soulieres D, Frelinger AL, et al. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol 2013; 6: 17
76. Gladwin MT, Kato GJ, Weiner D, et al. Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial. JAMA 2011; 305 (9): 893-902
77. Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med 2003; 168 (1): 63-9
78. Morris CR, Ansari M, Lavrisha L, et al. Arginine therapy for vaso-occlusive pain episodes in sickle cell disease. Blood (ASH Annual Meeting Abstracts) 2009; 114: 573
79. Morris CR, Kuypers FA, Lavrisha L, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica 2013; 98 (9): 1375-82
80. Morris CR, Suh JH, Hagar W, et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood 2008; 111 (1): 402-10
81. Niihara Y, Matsui NM, Shen YM, et al. L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells. BMC Blood Disord 2005; 5: 4
82. Lal A, Atamna W, Killilea DW, et al. Lipoic acid and acetyl-carnitine reverse iron-induced oxidative stress in human fibroblasts. Redox Rep 2008; 13 (1): 2-10
83. Hannemann A, Cytlak UM, Rees DC, et al. Effects of 5-hydroxymethyl-2-furfural on the volume and membrane permeability of red blood cells from patients with sickle cell disease. J Physiol 2014; 592 (Pt 18): 4039-49
84. Singh PC, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst Rev 2007 (4): CD003426
85. Nagalla S, Ballas SK. Drugs for preventing red blood cell dehydration in people with sickle cell disease. Cochrane Database Syst Rev 2012; 7: CD003426